Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 286.47M | 199.34M | 189.38M | 164.52M | 188.37M | 164.54M |
Gross Profit | 108.29M | 71.41M | 71.49M | 66.78M | 69.69M | 80.17M |
EBITDA | 6.86M | -34.29M | -6.03M | 3.89M | -6.00M | 25.95M |
Net Income | -45.78M | -59.21M | -32.46M | -15.91M | -17.69M | 4.25M |
Balance Sheet | ||||||
Total Assets | 273.60M | 249.92M | 273.60M | 302.65M | 344.73M | 272.33M |
Cash, Cash Equivalents and Short-Term Investments | 39.79M | 28.87M | 39.79M | 78.78M | 111.22M | 165.39M |
Total Debt | 51.78M | 56.37M | 51.78M | 48.22M | 67.45M | 32.19M |
Total Liabilities | 141.01M | 154.41M | 141.01M | 136.77M | 162.37M | 85.58M |
Stockholders Equity | 138.12M | 104.13M | 138.12M | 166.08M | 178.22M | 185.87M |
Cash Flow | ||||||
Free Cash Flow | -4.99M | -38.59M | -10.00M | -21.13M | -18.25M | 5.56M |
Operating Cash Flow | 5.04M | 6.01M | 8.02M | -2.27M | -2.47M | 14.16M |
Investing Cash Flow | -40.00M | -12.70M | -26.14M | 558.00K | -82.45M | -13.34M |
Financing Cash Flow | -16.73M | 19.43M | -10.48M | -25.65M | 11.97M | 92.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | 8.64B | 29.41 | 24.18% | 1.42% | 28.53% | 22.34% | |
60 Neutral | 95.47M | -12.97 | 0.00% | ― | -11.68% | -71.01% | |
56 Neutral | 86.09M | -25.53 | -80.50% | ― | -8.20% | -10.39% | |
56 Neutral | 19.76M | 2.45 | 69.48% | ― | -8.48% | 0.00% | |
50 Neutral | HK$67.96M | ― | -51.07% | ― | -20.66% | -77.84% | |
41 Neutral | 10.32M | -0.35 | 17.98% | ― | 14.64% | -81.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Raily Aesthetic Medicine International Holdings Limited reported its unaudited interim results for the six months ending June 30, 2025, revealing a significant decrease in revenue and an increased loss compared to the same period in 2024. The company experienced a drop in gross profit and other income, while expenses in selling, distribution, and administration also decreased. The overall loss for the period was attributed to both owners of the parent and non-controlling interests, indicating financial challenges that may impact stakeholders and the company’s market position.
Raily Aesthetic Medicine International Holdings Limited has announced a board meeting scheduled for 29 August 2025. The meeting will address the approval of the company’s unaudited interim results for the first half of 2025 and discuss potential dividend declarations, impacting the company’s financial disclosures and shareholder returns.
Raily Aesthetic Medicine International Holdings Limited announced the termination of its contractual arrangements with Hangzhou Beilifeier, as the latter shifts its strategic focus towards the sales of aesthetic medical equipment products. This move comes after the cessation of Hangzhou Beilifeier’s aesthetic medical services and the application for a medical device business license, removing restrictions on foreign ownership and allowing Raily to transfer equity interests and unwind previous agreements.
Raily Aesthetic Medicine International Holdings Limited has issued a profit warning, reporting a significant decline in revenue and an increase in losses for the first half of 2025. The company’s revenue fell to approximately RMB85 million, down from RMB117 million in the same period in 2024, while losses attributable to the parent company increased to around RMB8 million. The decline is attributed to intense market competition and increased expenses related to share options and research and development activities. The company advises shareholders and potential investors to exercise caution as the financial results are preliminary and subject to adjustments.
Raily Aesthetic Medicine International Holdings Limited announced a deemed disposal of equity interest in a subsidiary through an investment agreement with two investors. The transaction involves a capital injection by the investors, resulting in a significant reduction of Hangzhou Raily’s equity in the Target Company from 100% to 30%. This move is part of a strategy to reduce accumulated losses and improve the financial position of the subsidiary. The transaction is classified as a discloseable transaction under Hong Kong’s Listing Rules, requiring an announcement but not shareholder approval.
Raily Aesthetic Medicine International Holdings Limited has established a nomination committee to identify and recommend candidates for the board of directors, oversee board performance evaluations, and develop nomination guidelines. This move is expected to enhance the governance structure of the company, ensuring compliance with applicable laws and regulations, and potentially strengthening its market position by promoting diversity and independence within its board.